Should you buy AstraZeneca (AZN)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
AZN currently trades below the base anchor, in the lower half of the engine methodology range.
Engine methodology range — mechanically derived from pipeline gate outputs + peer-multiple inputs. Not an analyst price target. JSON-LD emission gated pending counsel review.
What the engine is tracking
- Wide Moat Strong Margins↑Improving
- Price Above Analyst Target↑Improving
- Overbought Euphoria Risk↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
→ Full pillar scorecard with all 5 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Moat Strong Margins
Trip ifOperating margin falls below 14% from current level of roughly 18%.
- P2Price Above Analyst Target
Trip ifPrice stays more than 8% above the analyst target from current 3.7% above.
- P3Overbought Euphoria Risk
Trip ifRSI falls below 50 from current 80 while price drops below the 200-day average.
- P4Weak Cash Conversion
Trip ifFree cash flow to net income conversion rises above 80% from current 51%.
- P5Modest Growth Valuation
Trip ifPEG ratio rises above 2.0 from current 1.32.
How the engine reached this verdict
TrendMatrix's engine output for AstraZeneca PLC (AZN) is HOLD_IF_HOLDING with medium conviction, score 6.0/10 at $183.88. None of the engine's positive-conviction paths (C-quality, D-momentum) cleared their gates — the F-path HOLD reflects balanced signals rather than directional conviction.
HOLD flips toward BUY_WAIT if reward-to-risk (NEGATIVE) clears AND a co-confirming gate triggers. HOLD flips toward SELL if any of the currently-passing gates drop below threshold OR three or more dimensions fall below 4 simultaneously.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $174.70 for existing positions. Asymmetric R:R is -0.15, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: AVOID at this asymmetry level (no fresh-capital deployment).
On the bull side: Sector modifier (Healthcare): +0.5; Strong earnings beat streak (3/4); Positive momentum. On the bear side: Analyst target reached - limited upside remaining; Euphoria warning: extreme positivity (+1.00) + overbought RSI 77; Overbought (RSI 77). Active engine warnings: V8: Target reached (-2.2% upside), V9 Gate Failed: ASYMMETRY:-0.1=NEGATIVE.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates AZN — 10-dimension breakdown →
Bull case
- ▸Sector modifier (Healthcare): +0.5
- ▸Strong earnings beat streak (3/4)
- ▸Positive momentum
Bear case
- ▸Analyst target reached - limited upside remaining
- ▸Euphoria warning: extreme positivity (+1.00) + overbought RSI 77
- ▸Overbought (RSI 77)